Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-08-06 DOI:10.1080/1750743X.2024.2377953

Fabiana Perrone, Federica Pecci, Michele Maffezzoli, Giulia Claire Giudice, Valeria Cognigni, Giulia Mazzaschi, Luca Cantini, Luca Santamaria, Francesco Paoloni, Marco Luigi Bruno Rocchi, Matilde Coriano', Alessandro Acunzo, Federico Quaini, Marcello Tiseo, Saini S Kamal, Rossana Berardi, Sebastiano Buti

{"title":"Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy.","authors":"Fabiana Perrone, Federica Pecci, Michele Maffezzoli, Giulia Claire Giudice, Valeria Cognigni, Giulia Mazzaschi, Luca Cantini, Luca Santamaria, Francesco Paoloni, Marco Luigi Bruno Rocchi, Matilde Coriano', Alessandro Acunzo, Federico Quaini, Marcello Tiseo, Saini S Kamal, Rossana Berardi, Sebastiano Buti","doi":"10.1080/1750743X.2024.2377953","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the different impact of each component of lipid profile in advanced cancer patients treated with immune checkpoints inhibitors (ICIs) according to neutrophil-to-lymphocyte ratio (NLR) value.Methods: We retrospectively collected total cholesterol (TC), triglycerides (TGs), low-density lipoproteins (LDL), high-density lipoproteins (HDL).Results: 407 patients were enrolled. In NLR <4 subgroup, TGs <150 mg/dl led to longer PFS (p = 0.01) and OS (p = 0.02) compared with TGs ≥150 mg/dl; LDL <100 mg/dl led to longer PFS (p = 0.004) and OS (p = 0.007) compared with LDL ≥100 mg/dl. In NLR ≥4 subgroup, TC >200 mg/dl led to longer PFS (p = 0.008) and OS (p = 0.004) compared with TC <200 mg/dl.Conclusion: We showed a distinct prognostic impact of lipid profile according to NLR.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"859-868"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457594/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2377953","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the different impact of each component of lipid profile in advanced cancer patients treated with immune checkpoints inhibitors (ICIs) according to neutrophil-to-lymphocyte ratio (NLR) value.Methods: We retrospectively collected total cholesterol (TC), triglycerides (TGs), low-density lipoproteins (LDL), high-density lipoproteins (HDL).Results: 407 patients were enrolled. In NLR <4 subgroup, TGs <150 mg/dl led to longer PFS (p = 0.01) and OS (p = 0.02) compared with TGs ≥150 mg/dl; LDL <100 mg/dl led to longer PFS (p = 0.004) and OS (p = 0.007) compared with LDL ≥100 mg/dl. In NLR ≥4 subgroup, TC >200 mg/dl led to longer PFS (p = 0.008) and OS (p = 0.004) compared with TC <200 mg/dl.Conclusion: We showed a distinct prognostic impact of lipid profile according to NLR.

查看原文本刊更多论文

中性粒细胞与淋巴细胞比率对接受免疫疗法的晚期癌症患者血脂状况的不同影响。

目的：根据中性粒细胞与淋巴细胞比率（NLR）值，研究血脂各组分对接受免疫检查点抑制剂（ICIs）治疗的晚期癌症患者的不同影响。方法我们回顾性地收集了总胆固醇（TC）、甘油三酯（TGs）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）。结果共纳入 407 名患者。与 TGs≥150 mg/dl 相比，NLR p = 0.01）和 OS（p = 0.02）；与 LDL≥100 mg/dl 相比，LDL p = 0.004）和 OS（p = 0.007）。在 NLR≥4 亚组中，与 TC 相比，TC >200 mg/dl 会延长 PFS（p = 0.008）和 OS（p = 0.004）：根据 NLR 的不同，我们发现血脂组合对预后有不同的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.